Melanoma Treatment Market Size, Share, Opportunities, And Trends By Type (Cutaneous Melanoma, Ocular Melanoma, Mucosal Melanoma), By Therapy (Surgery, Immunotherapy, Targeted, Chemotherapy, Radiation), And By Geography - Forecasts From 2025 To 2030
- Published : May 2025
- Report Code : KSI061610401
- Pages : 142
Melanoma Treatment Market Size:
The Melanoma Treatment Market is expected to grow from US$7.510 billion in 2025 to US$9.815 billion in 2030, at a CAGR of 5.50%.
Melanoma Treatment Market Trends:
In recent years, there has been a rise in the number of new cases reported due to climatic changes. These changes are increasing the incidence of melanoma patients worldwide, raising the demand for proper methods of treatment. If detected and treated early, the disease is almost always curable. The rising per capita income, better health facilities, growing health awareness, the availability of health insurance services, and advancement in medical science and bio-medicines are additionally factoring in the expansion of the market.
Geographically, North America dominates the market share. The high prevalence of skin-related cancer in the United States is a major factor contributing to the market's growth. By type, cutaneous melanoma is widely spread globally and caused by too much exposure to ultraviolet rays from the sun and indoor tanning. Based on therapy, targeted therapy is gaining market share due to fewer side effects and high efficiency rates.
Melanoma Treatment Market Growth Factors:
- Growing regulatory approvals.
The high emphasis and consequently the elevated investment in the development of efficient treatment options are likely to have a positive impact on the growth of the market. Treatment recommendations depend on many factors, and the increasing number of regulatory approvals has had the highest impact on market growth. In 2021, Aldesleukin, Binimetinib, Braftovi (Encorafenib), Cobimetinib Fumarate, Cotellic (Cobimetinib Fumarate), Dabrafenib Mesylate, etc., were some of the approved drugs for the treatment by the FDA. The emphasis of significant companies on introducing innovative treatment options and drugs will aid the market's growth in the coming years.
Melanoma Treatment Market Competitive Insights:
The market leaders for the melanoma treatment market are Merck & Co. Inc., Amgen Inc., Iovance Biotherapeutics, Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Eisai Co., Ltd., Novartis AG, Pfizer Inc., Sanofi, and AstraZeneca.
- In 2021, Oncosec Medical Inc. and Merck and Co. collaborated to study phase III metastatic melanoma.
- In 2021, Amgen completed the acquisition of Five Prime Therapeutics, a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share, and is set to acquire Teneobio, a privately held, clinical-stage biotechnology company.
- In 2020, Iovance Biotherapeutics, Inc. sold $500 million of its common stock, subject to market and other conditions, in an underwritten public offering. In 2021, there has been certain turmoil, and the company is looking for buy-out options.
- In 2019, Bristol-Myers Squibb Company and Celgene Corporation entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene for approximately $74 billion to create an innovative biopharma company.
- In 2020, Novartis AG acquired The Medicines Company, and in 2018 GlaxoSmithKline plc reached an agreement with Novartis for the buyout of Novartis’ 36.5% stake in their Consumer Healthcare Joint Venture for $13 billion.
- In 2020, FDA approved AstraZeneca and Merck & Co.'s drug selumetinib to treat neurofibromatosis type 1, or NF1, a rare and typically inherited disease that causes tumors to grow inside nerve sheaths. Merck joined AstraZeneca in developing and commercializing Koselugo as part of a deal that included the ovarian cancer drug Lynparza.
Melanoma Treatment Companies:
- Merck & Co. Inc.
- Amgen Inc.
- Iovance Biotherapeutics, Inc.
- Bristol-Myers Squibb
- F. Hoffmann-La Roche Ltd
Melanoma Treatment Market Segmentation:
- By Type
- Cutaneous Melanoma
- Ocular Melanoma
- Mucosal Melanoma
- By Therapy
- Surgery
- Immunotherapy
- Targeted Therapy
- Chemotherapy
- Radiation Therapy
- By Geography
- North America
- USA
- Canadá
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- UK
- Germany
- France
- Spain
- Others
- Middle East and Africa
- Saudi Arabia
- Israel
- Others
- Asia Pacific
- Japan
- China
- India
- Indonesia
- Taiwan
- Thailand
- Others
- North America
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Powers of Buyers
4.3.3. Threat of Substitutes
4.3.4. The Threat of New Entrants
4.3.5. Competitive Rivalry in Industry
4.4. Industry Value Chain Analysis
5. MELANOMA TREATMENT MARKET BY TYPE
5.1. Cutaneous Melanoma
5.2. Ocular Melanoma
5.3. Mucosal Melanoma
6. MELANOMA TREATMENT MARKET BY THERAPY
6.1. Surgery
6.2. Immunotherapy
6.3. Targeted Therapy
6.4. Chemotherapy
6.5. Radiation Therapy
7. MELANOMA TREATMENT MARKET BY GEOGRAPHY
7.1. Introduction
7.2. North America
7.2.1. United States
7.2.2. Canada
7.2.3. Mexico
7.3. South America
7.3.1. Brazil
7.3.2. Argentina
7.3.3. Others
7.4. Europe
7.4.1. Germany
7.4.2. France
7.4.3. United Kingdom
7.4.4. Spain
7.4.5. Others
7.5. Middle East and Africa
7.5.1. Saudi Arabia
7.5.2. UAE
7.5.3. Israel
7.5.4. Others
7.6. Asia Pacific
7.6.1. China
7.6.2. India
7.6.3. South Korea
7.6.4. Taiwan
7.6.5. Thailand
7.6.6. Indonesia
7.6.7. Japan
7.6.8. Others
8. COMPETITIVE ENVIRONMENT AND ANALYSIS
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrative
8.3. Mergers, Acquisition, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
9. COMPANY PROFILES
9.1. Merck & Co. Inc.
9.2. Amgen Inc.
9.3. Iovance Biotherapeutics, Inc,
9.4. Bristol-Myers Squibb
9.5. F. Hoffmann-La Roche Ltd
9.6. Eisai Co., Ltd.
9.7. Novartis AG
9.8. Pfizer Inc.
9.9. Sanofi
9.10. AstraZeneca
Merck & Co. Inc.
Amgen Inc.
Iovance Biotherapeutics, Inc.
F. Hoffmann-La Roche Ltd
Eisai Co., Ltd.
Novartis AG
Pfizer Inc.
Sanofi
AstraZeneca
Related Reports
Report Name | Published Month | Download Sample |
---|---|---|
Scar Treatment Market: Size, Growth, Trends, Forecast 2025-2030 | May 2025 | |
T-Cell Immunotherapy Market Size & Forecast 2030 | Free Sample | Jun 2025 | |
Global Cancer Biomarkers Market Insights: Growth, Forecast 2030 | May 2025 | |
Cancer Profiling Market Trends, Forecast 2024-2029 | Free Sample | Aug 2024 | |
Breast Cancer Treatment Market: Size, Trends & Forecast 2030 | May 2025 |